MedTrace Logo

P4 (Pregabalin for Peripheral Posttraumatic Pain)

NCT00292188 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 255

Last updated 2021-02-09

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of pregabalin compared to placebo in the treatment of posttraumatic peripheral neuropathic pain

Conditions

  • Neuralgia

Interventions

DRUG

pregabalin

pregabalin

DRUG

Placebo

placebo

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • Belgium
  • Canada
  • Denmark
  • Finland
  • Italy
  • Netherlands
  • Portugal
  • Romania
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00292188 on ClinicalTrials.gov